Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s175, 2023. DOI: 10.25251/skin.7.supp.175. Disponível em: https://skin.dermsquared.com/skin/article/view/1999. Acesso em: 19 apr. 2025.